Home Cart Sign in  
Chemical Structure| 69950-65-8 Chemical Structure| 69950-65-8

Structure of 69950-65-8

Chemical Structure| 69950-65-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 69950-65-8 ]

CAS No. :69950-65-8
Formula : C8H7NO3
M.W : 165.15
SMILES Code : COC(=O)C1=NC(C=O)=CC=C1
MDL No. :MFCD07367925
InChI Key :CERBENZCBVYKEF-UHFFFAOYSA-N
Pubchem ID :12575850

Safety of [ 69950-65-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 69950-65-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 6
Fraction Csp3 0.12
Num. rotatable bonds 3
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 40.9
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

56.26 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.93
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.83
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.68
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.28
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.35
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.7

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.56
Solubility 4.56 mg/ml ; 0.0276 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.59
Solubility 4.21 mg/ml ; 0.0255 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.04
Solubility 1.5 mg/ml ; 0.0091 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.72 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.62

Application In Synthesis of [ 69950-65-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 69950-65-8 ]

[ 69950-65-8 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 69950-65-8 ]
  • [ 180683-64-1 ]
  • N-BOC-N’-((6-methylpicol-2-yl)methyl)-trans-1,2-diaminocyclohexane [ No CAS ]
YieldReaction ConditionsOperation in experiment
85% [00232] N-BOC-N?-((6-methylpicol-2-yI)methyl)-trans-1 ,2- diaminocyclohexane (3). A batch of 349 mg (1 .63 mmol) N-BOO-trans-i ,2-diaminocyclohexane (1)14 was added to 269 mg (i .63 mmol) of methyl 6- formylpyridine-2-carboxylate (2)15 stirring in iO mL MeOH. Small aliquots of this reaction were removed and concentrated to dryness for NMR analysis to confirm full Schiff base formation. After 2 hours, the reaction was cooled to 000 and 66 mg (i .75 mmoL) NaBH4 was added in i mL MeOH forming a deep red solution within minutes.After 2 hours of stirring at 0C, the reaction was quenched with satd. NaHCO3(aq) and MeOH was removed via rotary evaporation. The volume of the resultant solution was doubled via addition of 0H2012 and the reaction was brought to pH 7 using i M HCI(aq). The organic layer was separated the aqueous phase washed 3x with 0H2012. The 0H2012 was pooled, dried over Na2504 and concentrated to 502 mg (i .38 mmol,85 %) of 3 as a yellow oil. 1H NMR (ODd3, 400 MHz), 6 (ppm): 7.97 (d, i H), 7.75 (t,iH), 7.54 (d, br, iH), 5.i8 (d, br, iH, NH), 4.08 (d, iH), 3.99-3.95 (m, 4H), 3.32 (m, br, i H), 2.37 (m, i H), 2.09-2.Oi (m, 2H), i .66-i .62 (m, 2H), i .4i (5, 9H), i .29-i .05 (m, 4H). 130 NMR (ODd3, iOO MHz), 6 (ppm): i65.95, i6i.82, i56.2i, i47.24, i37.33, i25.70, i23.35, 79.07, 64.67, 60.42, 54.75, 5i.28, 33.i8, 3i.97, 28.49,24.97, 24.6i. ESI (M + H) m/z = 364.3; calcd: 364.2.
  • 2
  • [ 791098-84-5 ]
  • [ 69950-65-8 ]
  • [ 1398583-87-3 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 69950-65-8 ]

Aldehydes

Chemical Structure| 499214-11-8

A131831 [499214-11-8]

6-Formylpicolinic acid

Similarity: 0.90

Chemical Structure| 64463-46-3

A128619 [64463-46-3]

Methyl 4-formylpicolinate

Similarity: 0.84

Chemical Structure| 133155-82-5

A174761 [133155-82-5]

Methyl 3-formylpicolinate

Similarity: 0.79

Chemical Structure| 125104-34-9

A215232 [125104-34-9]

Methyl 2-formylisonicotinate

Similarity: 0.74

Chemical Structure| 5431-44-7

A324883 [5431-44-7]

2,6-Pyridinedicarboxaldehyde

Similarity: 0.74

Esters

Chemical Structure| 13602-11-4

A441856 [13602-11-4]

Methyl 6-methylpyridine-2-carboxylate

Similarity: 0.95

Chemical Structure| 7170-36-7

A120886 [7170-36-7]

6-(Methoxycarbonyl)picolinic acid

Similarity: 0.91

Chemical Structure| 103931-19-7

A149803 [103931-19-7]

Methyl 6-ethylpicolinate

Similarity: 0.91

Chemical Structure| 5453-67-8

A149651 [5453-67-8]

Dimethyl pyridine-2,6-dicarboxylate

Similarity: 0.88

Chemical Structure| 39977-44-1

A110915 [39977-44-1]

Methyl 6-(hydroxymethyl)picolinate

Similarity: 0.88

Related Parent Nucleus of
[ 69950-65-8 ]

Pyridines

Chemical Structure| 13602-11-4

A441856 [13602-11-4]

Methyl 6-methylpyridine-2-carboxylate

Similarity: 0.95

Chemical Structure| 7170-36-7

A120886 [7170-36-7]

6-(Methoxycarbonyl)picolinic acid

Similarity: 0.91

Chemical Structure| 103931-19-7

A149803 [103931-19-7]

Methyl 6-ethylpicolinate

Similarity: 0.91

Chemical Structure| 499214-11-8

A131831 [499214-11-8]

6-Formylpicolinic acid

Similarity: 0.90

Chemical Structure| 5453-67-8

A149651 [5453-67-8]

Dimethyl pyridine-2,6-dicarboxylate

Similarity: 0.88